We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Safety monitoring and information (116)
- Compliance and enforcement (32)
- Import and export (28)
- Shortages and supply disruptions (17)
- Sunscreens (7)
- Advertising (6)
- COVID-19 (5)
- Labelling and packaging (4)
- Weight loss products (4)
- Breast implant hub (3)
- Manufacturing (3)
- Legislation (2)
- Metal-on-metal hip replacement implants hub (1)
Type of content
Search
1281 result(s) found, displaying 676 to 700
-
Market actionsRecall for product correction - potential for interruption of medicine delivery and/or infection due to needle breaking during use
-
-
Market actionsRecall for product correction - potential for interruption of insulin delivery and/or infection due to needle breaking during use
-
Market actionsRecall for product correction - increased risk of death for patients with symptomatic chronic heart failure
-
Market actionsMultiple devices which use auto servo ventilation/Adaptive Servo-Ventilation (ASV) therapy have been subject to recall actions
-
Safety alertsThe TGA has reviewed laparoscopic power morcellators and updated safety information to ensure their use aligns with current advice, including warnings about cancer risks and the need for containment systems during surgery.
-
Safety alertsJa Dera 100% Natural Weight Loss Supplement capsules pose a serious risk to your health and should not be taken
-
Safety alertsNo evidence to support routine blood monitoring at this time
-
Safety alertsSlim Fit capsules pose a serious risk to your health and should not be taken
-
Market actionsRecall for product correction - additional affected devices
-
-
Market actionsRecall - pumps will cease operation on 1 January 2016
-
Market actionsRecall - risk of adverse events due to unacceptably high level of arsenic
-
Safety alertsUpdate - adverse event monitoring
-
-
Market actionsRecall for product correction - fire risk from faulty component
-
Market actionsRecall for product correction - fire risk from faulty component
-
Market actionsThe following medicines (with brand names in brackets) should be returned to a pharmacy: alprazolam (Xanax), cabergoline (Dostinex and Cabaser), mefanamic acid (Ponstan), methotrexate (Methoblastin) and triazolam (Halcion)
-
Market actionsRecall - bottles supplied without child-resistant caps
-
Market actionsRecall for product correction - risk of sparking or fire due to damaged or cut wire
-
-
Market actionsRecall - counterfeit products may have defects and not be effective
-
Market actionsRecall for product correction - potential for insulin to not be delivered as intended
-
-